Clinical significance of Mena and Her-2 expression in breast cancer

被引:0
作者
Du, J. W. [1 ]
Xu, K. Y. [1 ]
Fang, L. Y. [1 ]
Qi, X. L. [1 ]
机构
[1] Anhui Univ Sci & Technol, Sch Med, Huainan City 232001, Anhui, Peoples R China
关键词
Breast cancer; Mena; Her-2; Immunohistochemistry; Clinicopathological parameter; HIGH-RISK;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to determine the expression patterns of Mena and Her-2 in breast cancer tissues and to explore their clinical significance and correlation with clinicopathological parameters. Methods: The expression of Mena and Her-2 was detected in 40 breast cancer tissues and 14 normal breast tissues by immunohistochemistry, and the relationship of Mena and Her-2 expression with clinicopathological parameters was analyzed. Results: Both Mena (70%) and Her-2 (40%) were more commonly expressed in breast cancer than in normal breast tissue (7.1%, 0%, respectively; p < 0.05); further, Mena and Her-2 expression in breast cancer were positively correlated (r = 0.530, p < 0.05). In comparing expression with clinicopathological parameters of tumor samples, Mena and Her-2 were both associated with axillary lymph node metastasis and TNM stage (p < 0.05), but not with patient age or pathological type. Conclusions: Mena and Her-2 are related to the malignancy degree and metastasis of breast cancer, and thus may play a coordinating role in the occurrence and progression of breast cancer.
引用
收藏
页码:455 / 458
页数:4
相关论文
共 16 条
  • [1] Breast cancer incidence and mortality trends in 16 European countries
    Botha, JL
    Bray, F
    Sankila, R
    Parkin, DM
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (12) : 1718 - 1729
  • [2] HER-2 Signaling and Inhibition in Breast Cancer
    Browne, B. C.
    O'Brien, N.
    Duffy, M. J.
    Crown, J.
    O'Donovan, N.
    [J]. CURRENT CANCER DRUG TARGETS, 2009, 9 (03) : 419 - 438
  • [3] Breast cancer statistics, 2011
    DeSantis, Carol
    Siegel, Rebecca
    Bandi, Priti
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (06) : 409 - 418
  • [4] The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors
    Di Modugno, F
    Mottolese, M
    Di Benedetto, A
    Conidi, A
    Novelli, F
    Perracchio, L
    Venturo, I
    Botti, C
    Jager, E
    Santoni, A
    Natali, PG
    Nisticò, P
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (05) : 1470 - 1478
  • [5] Genetic ablation of zyxin causes Mena/VASP mislocalization, increased motility and deficits in actin remodeling
    Hoffman, LM
    Jensen, CC
    Kloeker, S
    Wang, CLA
    Yoshigi, M
    Beckerle, MC
    [J]. JOURNAL OF CELL BIOLOGY, 2006, 172 (05) : 771 - 782
  • [6] Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients
    Kröger, N
    Milde-Langosch, K
    Riethdorf, S
    Schmoor, C
    Schumacher, M
    Zander, AR
    Löning, T
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (01) : 159 - 168
  • [7] Function and regulation of Ena/VASP proteins
    Kwiatkowski, AV
    Gertler, FB
    Loureiro, JJ
    [J]. TRENDS IN CELL BIOLOGY, 2003, 13 (07) : 386 - 392
  • [8] Liu Bing-bing, 2008, Chinese Journal of Pathology, V37, P266
  • [9] Long N, 2010, ASIAN PAC J CANCER P, V11, P107
  • [10] Mao Jie, 2005, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V30, P312